High Acceptability of an Orally Dispersible Tablet Formulation by Children

Leonie Wagner-Hattler1, Klara Kiene1, Julia Bielicki2

  • 1Department of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, 4056 Basel, Switzerland.

Insights

A new placebo orally dispersible tablet (pODT) formulation was highly accepted by children aged 2-10 years. This child-friendly dosage form shows promise for improving medication adherence in pediatric patients.

Area of Science:

  • Pediatric Pharmacology
  • Pharmaceutics
  • Drug Delivery Systems

Background:

  • There is a significant unmet need for child-appropriate oral medication formulations.
  • Existing oral dosage forms often present challenges for pediatric administration and adherence.

Purpose of the Study:

  • To evaluate the acceptability of a novel placebo orally dispersible tablet (pODT) formulation in children.
  • To assess the feasibility of administering this new dosage form to pediatric patients.

Main Methods:

  • A cross-sectional acceptability study was conducted with 40 children aged 2 to 10 years.
  • A 5 mm monolithic pODT containing calcium carbonate/calcium phosphate was administered.
  • Acceptability was assessed via parent questionnaires, staff ratings, and a Facial Hedonic Scale for older children.

Main Results:

  • The pODT formulation demonstrated very high acceptability, with 93% of parents and all questioned children finding it acceptable or very acceptable.
  • Study staff reported no problems with administration, and no children exhibited distress.
  • The formulation was rated positively for ease of administration and acceptance.

Conclusions:

  • The novel pODT is a child-friendly and convenient option for oral drug administration in pediatric populations.
  • This formulation is expected to significantly enhance drug adherence among children.
  • The findings support the development of orally dispersible tablets for pediatric use.

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
54
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
82
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
81
Factors Affecting Dissolution: Particle Size and Effective Surface Area01:23

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.3K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
62
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
252